Sun Ruifang, Liu Zhigang, Wang Lumin, Lv Weidong, Liu Jia, Ding Caixia, Yuan Yong, Lei Guangyan, Xu Changfu
Department of Pathology, School of Medicine, Xi'an Jiaotong University, 76 Yanta West Road, Xi'an, 710061, Shaanxi, People's Republic of China.
Department of Thoracic Surgery, Tumor Hospital of Shaanxi Province, 309 Yanta West Road, Xi'an, Shaanxi, People's Republic of China.
Tumour Biol. 2015 Sep;36(9):7195-204. doi: 10.1007/s13277-015-3361-y. Epub 2015 Apr 18.
Paclitaxel can exert therapeutic effects by interacting with microtubules. Stathmin and β-III-tubulin, which have impact on microtubule activity, are believed to be involved in the chemotherapy. The purpose of the present study was to evaluate the associations between stathmin and β-III-tubulin expression and treatment response and survivals in patients with non-small cell lung cancer (NSCLC). Two hundred thirty-eight patients who were treated by platinum-based chemotherapy were enrolled in this study, among them, 111 patients also received paclitaxel treatment. Formalin-fixed and paraffin-embedded tumor tissues were collected for messenger RNA (mRNA) and protein detection. We assessed the associations of the two molecules with treatment response and survival outcome. High level of stathmin exhibited poor response to chemotherapy (for mRNA, P = 0.041; for protein, P = 0.017). Overexpression of stathmin was associated with shorter overall survival (for mRNA, P = 0.012; for protein, P = 0.014) and progression-free survival (for mRNA, P = 0.039; for protein, P = 0.022). Of note, this association was only observed in patients who were treated by both platinum and paclitaxel. Similar effects were not observed for β-III-tubulin. The findings demonstrated that paclitaxel effect may be interfered with stathmin; overexpression of stathmin is a predictive marker for a worse prognosis in patients with NSCLC who were treated by both platinum and paclitaxel chemotherapy.
紫杉醇可通过与微管相互作用发挥治疗作用。对微管活性有影响的Stathmin和β-III-微管蛋白被认为参与了化疗过程。本研究的目的是评估Stathmin和β-III-微管蛋白表达与非小细胞肺癌（NSCLC）患者治疗反应及生存率之间的关联。本研究纳入了238例接受铂类化疗的患者，其中111例患者还接受了紫杉醇治疗。收集福尔马林固定、石蜡包埋的肿瘤组织用于信使核糖核酸（mRNA）和蛋白质检测。我们评估了这两种分子与治疗反应及生存结果之间的关联。Stathmin水平高显示对化疗反应较差（mRNA检测，P = 0.041；蛋白质检测，P = 0.017）。Stathmin过表达与总生存期缩短（mRNA检测，P = 0.012；蛋白质检测，P = 0.014）和无进展生存期缩短（mRNA检测，P = 0.039；蛋白质检测，P = 0.022）相关。值得注意的是，这种关联仅在同时接受铂类和紫杉醇治疗的患者中观察到。β-III-微管蛋白未观察到类似效应。研究结果表明，Stathmin可能会干扰紫杉醇的作用；Stathmin过表达是接受铂类和紫杉醇化疗的NSCLC患者预后较差的预测标志物。
